WO1997033879A1 - Composes et methodes d'inhibition selective de l'activation du recepteur a3 de l'adenosine chez l'homme - Google Patents

Composes et methodes d'inhibition selective de l'activation du recepteur a3 de l'adenosine chez l'homme Download PDF

Info

Publication number
WO1997033879A1
WO1997033879A1 PCT/US1997/003648 US9703648W WO9733879A1 WO 1997033879 A1 WO1997033879 A1 WO 1997033879A1 US 9703648 W US9703648 W US 9703648W WO 9733879 A1 WO9733879 A1 WO 9733879A1
Authority
WO
WIPO (PCT)
Prior art keywords
adenosine
treating
compound
patient
formula
Prior art date
Application number
PCT/US1997/003648
Other languages
English (en)
Inventor
Marlene A. Jacobson
Richard Norton
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9610365.0A external-priority patent/GB9610365D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of WO1997033879A1 publication Critical patent/WO1997033879A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Definitions

  • the present invention concerns the use of compounds as selective antagonists of the A3 adenosine receptor subtype for preventing mast cell degranulation and are therefore useful in the treatment or prevention of disease states induced by activation of the A3 receptor and mast cell activation.
  • disease states include but are not limited to asthma, myocardial reperfusion injury, allergic reactions including but not limited to rhinitis, poison ivy induced responses, urticaria, scleroderma, arthritis, other autoimmune diseases and inflammatory bowel diseases.
  • the selective antagonists are selective for the A3 adenosine receptor over the A 1 , A2a, and A2b adenosine receptors.
  • adenosine The actions of adenosine are mediated through G -protein coupled receptors, the Al, A2a, A2b and A3 adenosine receptors.
  • the adenosine receptors were initially classified into Al and A2 subtypes on the basis of pharmacological criteria and coupling to adenylate cyclase (Van Caulker, D., Muller, M. and Hamprecht, B. (1979) J. Neurochem., 55:999-1003).
  • Adenosine exhibits diverse and potent physiological actions in the cardiovascular, nervous, pulmonary, renal and immune systems. Adenosine has been demonstrated to terminate superventricular tachycardia through blockage of atrioventricular nodal conduction (J.P. DiMarco et al, (1985) J. Am. Col. CardioL, 6:417-425, A. Munoz et al, (1984) Eur. Heart J., 5:735-738). Adenosine is a potent vasodilator except in the kidney and placenta (R.A. Olsson, (1981) Ann. Rev. Physiol, 45:385-395).
  • Adenosine produces bronchoconstriction in asthmatics but not in nonasthmatics (Cushly et al, 1984, Am. Rev. Respir. Dis., 729:380-384). Adenosine has been implicated as a preventative agent and in treatment of ventricular dysfunction following episodes of regional or global ischemia (M.B. Forman and C.E. Velasco (1991) Cardiovasc. Drugs and Therapy, 5:901-908) and in cerebral ischemia (M.C. Evans et al, (1987) Neurosci. Lett., 55:287, D.K.J.E.,Von Lubitz et al, (1988) Stroke, 79:1133).
  • Adenosine receptor agonists, antagonists and binding enhancers have been identified and implicated for usage in the treatment of physiological complications resulting from cardiovascular, pulmonary, renal and neurological disorders.
  • Adenosine receptor agonists have been identified for use as vasodilators ((1989) FASEB. J., 5(4) Abs 4770 and 4773, (199107. Med. Chem., (1988) 34:2570), antihypertensive agents (D.G. Taylor et al, FASEB J., (1988) 2:1799), and anti-psychotic agents (T.G. Heffner et al, (1989) Psychopharmacology, 95:31-38).
  • Adenosine receptor agonists have been identified for use in improving renal function (R.D.
  • the invention concerns new methods for inhibiting activation of the human A3 adenosine receptor by adenosine, by treating a patient in need thereof with a compound of the formula
  • R is selected from the group consisting of
  • A3 adenosine receptor antagonists referred to hereinafter as A3 adenosine receptor antagonists.
  • the invention includes a method for achieving blockade of the vasoconstrictive response induced through adenosine activation of the A3 adenosine receptor subtype, which comprises treating the patient with an A3 adenosine receptor antagonist described above.
  • the invention also includes a method for treating or preventing myocardial ischemia, inflammation, brain arteriole diameter constriction, and the release of allergic mediators, which comprises treating the patient with an A3 adenosine receptor antagonist described above.
  • the invention also includes a method for treating or preventing asthma, myocardial reperfusion injury, rhinitis, poison ivy induced responses, urticaria, scleroderma, arthritis, and inflammatory bowel diseases which comprises treating the patient with an A3 adenosine receptor antagonist described above.
  • the invention also includes a method for preventing mast cell degranulation in a human which comprises treating the patient with an A3 adenosine receptor antagonist described above.
  • Adenosine, adenosine metabolites and other A3 adenosine receptor agonists induce mast cell degranulation.
  • Mast cell activation promotes the release of enzymes, bioactive amines and arachidonic acid metabolites which causes vasoconstriction, edema, leukocyte accumulation, and ultimately, tissue damage.
  • Mast cell degranulation is associated with myocardial reperfusion injury, hypersensitivity reactions such as asthma, allergic rhinitis, urticaria, ischemic bowel disease, autoimmune diseases including autoimmune inflammation, and atopic dermatitis.
  • the invention consists of administering an inhibitory effective amount of the A3 adenosine receptor antagonist to treat or prevent these diseases and pathologic effects that result from mast cell degranulation.
  • diseases amenable to treatment by the method of this invention include, but are not limited to, human diseases such as Addison's disease, autoimmune hemolytic anemia, Crohn's disease, Goodpasture's syndrome, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopinic purpura, Insulin-dependent diabetes militus, multiple sclerosis, myasthenia gravis, Pemphigus vulgaris, pernicious anemia, poststreptococcal glomerulonephritis, psoriasis, rheumatoid arthritis, scleroderma, Sjogren's syndrome, spontaneous infertility, and systemic lupus erythematosus, and animal skin disorders and allergies.
  • human diseases such as Addison's disease, autoimmune
  • the method provides a means for preventing or treating disease states associated with vascular constriction induced through activation of the A3 subtype of the adenosine receptor.
  • the method comprises contacting said receptor in the vasculature with an amount of A3 adenosine receptor antagonist which selectively blocks activation of the A3 adenosine receptor subtype on granulocytes, including mast cells, exhibiting the A3 adenosine receptor.
  • A3 adenosine receptor antagonists are used to effect a reduction in vasoconstriction in the vasculature without any substantial effect (binding or blockade) of the A2a or A2b subtypes of the adenosine receptor.
  • the methods involve inhibiting activation of the human A3 adenosine receptor by adenosine, by treating the patient in need thereof with a compound of the formula
  • R is selected from the group consisting of
  • R is hydrogen, Cl-4 alkyl or Cl-4 alkyloxy. In one embodiment of this class, R is -OCH3.
  • the invention also includes compounds having the formula
  • R is selected from the group consisting of fluorine, iodine, C2-4 alkyl, C3-4 alkyloxy, and Cl-4 alky lcarboxy.
  • the invention also includes use of a compound of the invention or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing asthma, myocardial reperfusion injury, rhinitis, poison ivy induced responses, urticaria, scleroderma, arthritis, and inflammatory bowel diseases in a mammal.
  • alkyl means straight or branched alkane containing 1 to about 4 carbon atoms, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl.
  • alkyloxy or includes an alkyl portion where alkyl is as defined above, e.g., methyloxy, propyloxy, and butyloxy.
  • alkylcarboxy includes an alkyl portion where alkyl is as defined above, e.g., methylcarboxy, propylcarboxy, and butylcarboxy.
  • oxy means an oxygen (O) atom.
  • salts shall mean non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
  • Representative salts include the following salts: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methyl
  • A3 adenosine receptor antagonists useful for the present invention can be prepared according to the general procedure exemplified in El-Kerdawy, Synthesis of Novel Thiazolopyrimidine and Thiazolothiatriazine Derivatives; Bull. Fac. Cairo Univ.,: Vol 31. No. 1. (1993).
  • the A3 adenosine receptor antagonists useful for the present invention can be administered in such oral forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. Likewise, they may be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed.
  • An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the A3 adenosine receptor antagonist required to prevent, counter, or arrest the progress of the condition.
  • Oral dosages of the A3 adenosine receptor antagonists when used for the indicated effects, will range between about 1 ⁇ g per kg of body weight ( ⁇ g/kg) to about 10 mg/kg intravenously, e.g., 10 ⁇ g/kg, 1 mg/kg, or 5 mg/kg.
  • doses range from between 0.1 mg to 1 gram, e.g., 1 mg, 100 mg and 500 mg.
  • A3 adenosine receptor antagonists useful for the present invention may be administered in divided doses of two, three, or four times daily.
  • the most preferred doses of A3 adenosine receptor antagonist will range from about 0.05 to about 0.25 ⁇ g/kg/minute during a constant rate infusion, e.g., 0.15 ⁇ g/kg/minute.
  • a composition of the invention having 0.05 mg/ml of active ingredient should be aclministered at a rate of between about 0.001 and 0.005 ml/kg/min, e.g., 0.003 ml/kg/min.
  • Compositions of the invention containing higher concentrations of active ingredients should be administered at correspondingly lower rates.
  • preferred A3 adenosine receptor antagonists useful for the present invention can be in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
  • the dosage administration will, of course, be continuous rather that intermittent throughout the dosage regime.
  • the A3 adenosine receptor antagonists herein described form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as "carrier” materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with convention pharmaceutical practices.
  • carrier suitable pharmaceutical diluents, excipients or carriers
  • the A3 adenosine receptor antagonist component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like;
  • an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like
  • the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn-sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene giycol, waxes and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • the A3 adenosine receptor antagonists useful for the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • A3 adenosine receptor antagonists useful for the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl- methacrylamide-phenol, polyhydroxy-ethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
  • a drug for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
  • Adenosine has been shown to produce bronchoconstriction in asthmatics but not in nonasthmatics, demonstrating that adenosine plays a role in the etiology of this disease state (Cushly et al, AM. Rev. Respir. Dis., (129) pp. 380-384 (1984)).
  • Adenosine mediated bronchoconstriction on bronchial rings in asthmatics is blocked in vitro by a combination of histamine and leukotriene antagonists (Bjorck et al, Am. Rev. Resp. Dis., 1992, (145) pp.
  • A3 adenosine receptor antagonists identified herein as being useful to antagonize the A3 adenosine receptor can be used in conjunction with other therapies, including co-administration of anti-histamine, leukotriene blockade or other anti-allergic mediator therapies and A3 specific antagonists.
  • Blockade of A3 adenosine receptor mediated action in the vasculature is useful to treat and prevent disease states in humans.
  • Adenosine potentiates the release of granule contents from mast cells isolated from rat peritoneum (see Lohse et al, N.-S. Arch. Pharmacol, (335) pp. 555-560 (1987) and Marquardt et al, J. Immunol, (120) pp. 871-878 (1978)), which causes constriction in some vascular beds resulting in C5a-induced myocardial ischemia (see Ito et al, Am. J. Physiol, (264) ⁇ Heart Circ. Physiol, (33) pp.
  • the trigger for mast cell degranulation is usually thought to be an allergen. Allergens are endocytosed by marcrophages and degraded. The resulting fragments are displayed on T lymphocytes. B lymphocytes are stimulated to mature into plasma cells which are able to secrete allergen-specific molecules known as immunoglobulin E. These antibodies attach to receptors on mast cells in tissue and on basophils circulating in blood to trigger degranulation (see L. Lichtenstein, 5c/. Am., (269) pp. 116-125 (1993)). Activation of A3 adenosine receptors can produce mast cell degranulation and enhance the effect of allergens.
  • Adenosine and antigens trigger an influx of calcium to induce mast cell granules to release their contents an promote synthesis and release of cytokines, prostaglandins and leukotrienes.
  • the various chemicals released by mast cells are responsible for many allergic symptoms. Long term release of these chemicals can induce basophils, eosinophils, and other cells flowing through blood vessels to migrate into the tissue. Migration is promoted due to the expression and activation of adhesion molecules on the circulating cells and on vascular endotheilial cells. The circulating cells adhere to the endothelial cells, roll among them, and eventually cross into the surrounding matrix. These recruited cells secrete chemicals of their own that damage tissue. Thus, there are long term secondary effects which may also be prevented by specific blockade of mast cell degranulation.
  • the A3 adenosine receptor antagonists are useful for treating patients prone to reperfusion injury, including those with coronary artery diseases in general, and patients anticipating the opening of occluded arteries (reperfusion) by various interventions, e.g., coronary artery bypass grafts, angioplasty or thrombolytic therapy.
  • coronary artery bypass grafts e.g., coronary artery bypass grafts, angioplasty or thrombolytic therapy.
  • Heller, LJ. and Regal, J.F. "Effect of adenosine on histamine release and atrioventricular conduction during guinea pig cardia anaphylaxis" Circ. Res., (62) pp. 1147-1158 (1988), suggest that mast cell degranulation is involved in ischemia/reperfusion injury.
  • Adenosine-induced mast cell degranulation during a period of transient ischemia may be responsible for the phenomenon of preconditioning (i.e., a transient ischemic episode reduces myocardial damage resulting from a subsequent prolonged ischemic episode). Accordingly, mast cells are temporarily depleted of damaging mediators during the preconditioning period.
  • Heller et al found increases in levels of endogenous adenosine during cardiac anaphylaxis contributed to the development of atrioventricular conduction delays and that increases in levels of adenosine before antigen challenge may increase the amount of histamine released during cardiac anaphylactic reactions.
  • the A3 receptor antagonists can be used in adjunct therapy with recanulation such as angioplasty and thrombolytic agents for the treatment of reperfusion injury.
  • recanulation such as angioplasty and thrombolytic agents for the treatment of reperfusion injury.
  • a probable course of treatment would be acute i.v. formulation followed by at least two weeks oral treatment for those patients undergoing angioplasty or thrombolytic therapy with, for example, TPA or steptokinase.
  • chronic oral therapy would be appropriate.
  • the human A2a, A2b and A3 receptor subtype cDNAs were subcloned into the expression vectors pSVL (Pharmacia, Columbus, Ohio), CMV5 (Mumby et al, PNAS, (87) pp. 728-732 (1990)) pCDNAl or pREP (Invitrogen).
  • Transient expression in COS7 cells monkey kidney cell line, ATCC CRL 1651, ATCC, Rockville, MD
  • Doyl et al. WO 95/11681 was accomplished by transfection of the cloned adenosine receptor cDNAs under the control of the S V40 promoter into mammalian cells, such as COS7.
  • Membranes prepared from the transfected cells were utilized for the determination of binding affinity, selectivity and specificity of the human adenosine receptors for various ligands.
  • Stable expression of the human adenosine receptors in mammalian cells was achieved after integration of the transfected cDNA into the chromosomes of the host cells.
  • These stable cell lines constituently express the cloned human adenosine receptors and can be propagated infinitely.
  • Stable cell lines expressing the human adenosine subtype cDNAs individually can be used in the binding assay to measure the affinity and selectivity of the receptors for adenosine agonists, antagonists and enhancers.
  • Membranes prepared from transfected COS7 and CHO cells were utilized in a binding assay to measure the affinity of agonists and antagonists on the human adenosine receptors.
  • Monolayer cell culture of transfected COS7 cells were dissociated with 1 mM EDTA in phosphate buffered saline and resuspended in 5 mM Tris, pH 7.6/10 mM MgCl2- The cells were subjected to freeze-thaw lysis and the suspension was homogenized in a glass dounce homogenizer.
  • the membranes were pelleted, resuspended in binding buffer, 50 mM Tris pH 7.6/10 mM MgCl2 and incubated with adenosine deaminase before the binding assay.
  • the binding assay was performed by incubating 50-100 ⁇ g of membranes with increasing concentrations of radiolabeled adenosine agonists.
  • Bound ligand was separated from free ligand by filtration on a Skatron cell harvester equipped with a receptor binding filtermat. Bound radioactivity was measured by scintillation counting. Binding data were analyzed by the use on nonlinear regression curve fitting program Graph Pad InPlot, Version 3.0 (Graph Pad Software, San Diego).
  • Ki values were calculated using the Cheng-Prusoff derivation (Cheng, Y.C. and Prusoff, H.R. (1973) Biochem. Pharmacol. 22, 3099-3108).
  • the affinities of agonists and antagonists on human adenosine receptor subtypes were measured in competition binding assays using the radiolabeled adenosine agonists [3HJ-CGS21680 (2-(p-(2-carboxyethyl)- phenylamino)-5'-N-ethyl-carboxamidoadenosine) for A2a receptors and, [3H]-5'-N-ethylcarboxamido adenosine ([3HJ-NECA), or [125i]-N6- aminobenzyl adenosine (125I-ABA) for A3 receptors.
  • Nonselective binding was determined with 1 ⁇ M I- ABA for the A3 receptor and 10 ⁇ M NECA for
  • cAMP accumulation were measured in stably transfected CHO cells expressing the human adenosine receptor subtypes.
  • CHO cells were washed twice in phosphate buffered saline (PBS) and detached in 0.2% EDTA in PBS. After pelleting at 800 rpm for 10 min, cells were resuspended in KRH buffer (140 mM NaCl/5 mM KC1/2 mM CaCl2/1.2 mM MgS04/1.2 mM KH2PO4/6 mM glucose/25 mM Hepes buffer, pH 7.4), washed once in KRH buffer and resuspended at 10? cells/mL.
  • KRH buffer 140 mM NaCl/5 mM KC1/2 mM CaCl2/1.2 mM MgS04/1.2 mM KH2PO4/6 mM glucose/25 mM Hepes buffer, pH 7.4
  • the cell suspension (100 ⁇ L) was mixed with 100 ⁇ L of KRH buffer containing 200 ⁇ M of the phosphodiesterase inhibitor Ro 20-1724 and incubated at 37°C for 15 minutes. Antagonists were preincubated for 10 minutes before adding 5 ⁇ M forskolin and 60 ⁇ M adenosine. After 10 minutes, 400 ⁇ L of 100 mM acetic acid was added and the sample was boiled for 5 minutes. The supernatant was recovered by centrifugation for 15 minutes and cAMP levels were dete ⁇ nined by radioimmunoassay (RIANEN kit, DuPont/NEN) using the acetylation protocol.
  • RIANEN kit radioimmunoassay
  • the increase in cAMP accumulation was induced by addition of adenosine (10 ⁇ M) and incubated at 37°C for 20 minutes before termination with acidic acid and RIA analysis.
  • the ability to block the agonist-induced increase in cAMP was measured by preincubating antagonists for 10 minutes before adding 10 ⁇ M adenosine.
  • an A3 adenosine receptor antagonist with high affinity for the receptor can be administered at dosages lower than A3 adenosine receptor antagonists with low affinity.
  • A3 adenosine receptor antagonists having a pKi of greater than about 7 for the A3 receptor and below about 6 for other adenosine receptor subtypes may be administered by any effective means to achieve either localized or systemic contact of the A3 adenosine receptor antagonist with target A3 adenosine receptors, including intravenous, intramuscular, intrasynovial, intranasal, nebulized intrapulmanory, intraperitoneal or other common means for administration of therapeutic compounds. Dosages of between about 1 ⁇ g/kg and 10 mg/kg are envisioned, as necessary, to achieve the desired effect of A3 adenosine receptor blockade.
  • A2a and A2b receptor subtypes were determined. Activity on A2a and A2b receptor subtypes was measured at a single concentration of antagonist (10 ⁇ M) and is reported as % inhibition of specific binding.
  • the binding data shows the compounds described above have nM affinity for the A3 receptor and are highly selective for the A3 receptor.
  • Such A3 selectivity minimizes or eliminates side effects associated with other adenosine receptor subtypes such as cardiovascular effects, e.g., hypotension, bradycardia, arrthymias, and CNS effects, e.g., sedation, locomotion.
  • vasoconstrictor action of adenosine in hamster cheek pouch arterioles is described here, and blockade of this response by A3 adenosine receptor antagonists is demonstrated.
  • Adenosine, inosine, cromolyn, compound 48/80, methylene blue, acetylcholine, and components for saline solutions used to bathe arterioles are obtained from Sigma.
  • 8(p-sulphophenyl)theo-phylline was obtained from Research Biochemicals, Inc. (Natick, MA).
  • Arterioles (luminal diameter approximately 60 ⁇ m) are dissected from male Golden hamster cheek pouches, transferred to a 37°C tissue chamber, and cannulated at both ends (see During et al, Am. J. Physiol, (241) (Heart Circ. Physiol, (10) pp. H108-H116 (1981); Duling et al, Microcirculatory Technology, edited by CH. Baker and W.G. Nastuk, Orlando Academic Press, pp. 265-280 (1986)).
  • the constrictor response is not mediated through an adenosine A2 receptor.
  • the constrictor response is assymetrical and focal in nature, such that it was initiated at discrete points and subsequently spread along the entire vessel, suggesting discrete sites of action of adenosine.
  • Examination of the abluminal surface of the vessel after staining with methylene blue reveal large numbers of mast cells closely associated with the vessel wall. Following exposure to adenosine, mast cells are found to be degranulated, suggesting the involvement of mast cell granule contents in the constrictor response.
  • the myocardial region at risk and infarct size are determined by the triphenyltetrazolium histochemical technique and regional myocardial blood flow by radioactive microspheres. Coronary sinus LDH activity and histamine concentrations were measured at various times throughout the experiments and myeloperoxidase activity was determined at the conclusion of the experiments as an index of neutrophil infiltration into the ischemic-reperfused mycocardium. Ten dogs were included in this preliminary study, 4 in the vehicle-treated group and 6 in the antagonist treated group.
  • the A3 adenosine receptor antagonists can also be administered by inhalation.
  • Commercially available nebulizers for liquid formulations including jet nebulizers and ultrasonic nebulizers are useful for such administration.
  • Liquid formulations can be directly nebulized and lyophilized powder can be nebulized after reconstitution.
  • the antagonists are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulizers.
  • the compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device.
  • An exemplary delivery system for inhalation is a metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of an A3 adenosine receptor antagonist in suitable propellants, such as fluorocarbons or hydrocarbons.
  • MDI metered dose inhalation
  • the aerosol formulation is prepared according to conventional procedures and administered to a patient experiencing an asthmatic episode.
  • Tablets and capsules represent a dosage form suitable for patients suffering from allergies caused by airbome allergens.
  • compound JLJ. in a free-flowing form such as powder or granules, is introduced to a suitable machine, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent.
  • a suitable machine optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent.
  • each tablet contains from about 2.5 mg to about 500 mg of the antagonist and each cachet or capsule contains from about 2.5 to about 500 mg of the antagonist.
  • a patient suffering from allergies caused by airborne allergens takes 1 or 4 tablets or capsules each day to alleviate and/or prevent allergy symptoms
  • preparations for topical application to the skin whereby the A3 adenosine receptor antagonists are effective in the treatment and control of skin diseases characterized by rapid rates of cell proliferation and/or abnormal cell proliferation, e.g., psoriasis.
  • a pharmaceutical formulation comprising an A3 adenosine receptor antagonist (usually in concentrations in the range of from about 0.001 percent to about 10 percent, preferably from about 0.1 percent to about 5 percent), together with a non-toxic, pharmaceutically acceptable topical carrier, is applied several times daily to the affected skin until the condition is improved. Topical applications may then be continued at less frequent intervals (e.g., once a day) to control mitosis in order to prevent return of severe disease conditions.
  • the topical pharmaceutical compositions according to the invention may also include one or more preservatives or bacteriostatic agents, e.g., methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chlorides, etc. Ointment mg/g
  • a patient suffering from psoriasis administers the ointment to affected areas several times each day.
  • Compound U is used in adjunct therapy with recanulation such as angioplasty and thrombolytic agents for the treatment of reperfusion injury.
  • compositions of the compound such as Tablet mg/tablet
  • Microcrystalline Cellulose 415 Pregelatinized Starch 43.5 Magnesium Stearate 2.5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Méthode d'inhibition de l'activation du récepteur A3 de l'adénosine chez l'homme, consistant à traiter ce récepteur par un composé de formule (I), par exemple (II).
PCT/US1997/003648 1996-03-15 1997-03-11 Composes et methodes d'inhibition selective de l'activation du recepteur a3 de l'adenosine chez l'homme WO1997033879A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1348596P 1996-03-15 1996-03-15
US60/013,485 1996-03-15
GBGB9610365.0A GB9610365D0 (en) 1996-05-17 1996-05-17 Compounds and methods for selectively inhibiting activation of the human A3 adenosine receptor
GB9610365.0 1996-05-17

Publications (1)

Publication Number Publication Date
WO1997033879A1 true WO1997033879A1 (fr) 1997-09-18

Family

ID=26309354

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/003648 WO1997033879A1 (fr) 1996-03-15 1997-03-11 Composes et methodes d'inhibition selective de l'activation du recepteur a3 de l'adenosine chez l'homme

Country Status (1)

Country Link
WO (1) WO1997033879A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044756A1 (fr) * 1999-01-28 2000-08-03 Takeda Chemical Industries, Ltd. Composes de thiazolopyrimidine, et methodes de preparation et d'utilisation correspondantes
WO2003048120A2 (fr) 2001-11-30 2003-06-12 Osi Pharmaceuticals, Inc. Composes specifiques des recepteurs a1 et a3 de l'adenosine et leurs utilisations
US6620825B1 (en) 1997-10-27 2003-09-16 Takeda Chemical Industries, Ltd. Adenosine A3 receptor antagonists
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6800633B2 (en) 1998-06-02 2004-10-05 Osi Pharmaceuticals, Inc. Pyrrolo[2,3d]pyrimidine compositions and their use
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
WO2005063246A1 (fr) * 2003-12-29 2005-07-14 Can-Fite Biopharma Ltd. Methode de traitement de la sclerose en plaques
EP1731520A1 (fr) 1999-12-02 2006-12-13 OSI Pharmaceuticals, Inc. Dérivés de pyrrolo[2,3-d]pyrimidine comme antagonistes d'adénosine A1, A2A et A3
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2008055711A2 (fr) * 2006-11-09 2008-05-15 Centre De Recherche Public De La Sante Utilisation d'un antagoniste de l'adénosine
US7423144B2 (en) 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
US7501407B2 (en) 2001-12-20 2009-03-10 Osi Pharmaceuticals, Inc. Pyrimidine A2B selective antagonist compounds, their synthesis and use
US7645754B2 (en) 2001-12-20 2010-01-12 Osi Pharmaceuticals, Inc. Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use
US7732424B2 (en) 2005-11-30 2010-06-08 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
US7863253B2 (en) 2004-09-20 2011-01-04 Inotek Pharmaceuticals Corporation Purine Derivatives and methods of use thereof
US9278991B2 (en) 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
US9289383B2 (en) 2010-03-26 2016-03-22 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans
US9370530B2 (en) 2010-01-11 2016-06-21 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
US9522160B2 (en) 2013-03-15 2016-12-20 Inotek Pharmaceuticals Corporation Ophthalmic formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BULL. FAC. PHARM. (CAIRO UNIV.), 1993, Vol. 31, No. 1, EL-KERDAWY M.M. et al., "Synthesis of Novel Thiazolopyrimidine and Thiazolothiatriazine Derivatives", pages 67-74. *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620825B1 (en) 1997-10-27 2003-09-16 Takeda Chemical Industries, Ltd. Adenosine A3 receptor antagonists
US7429574B2 (en) 1998-06-02 2008-09-30 Osi Pharmaceuticals, Inc. 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6800633B2 (en) 1998-06-02 2004-10-05 Osi Pharmaceuticals, Inc. Pyrrolo[2,3d]pyrimidine compositions and their use
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6583146B1 (en) 1999-01-28 2003-06-24 Takeda Chemical Industries, Ltd. Thiazolopyrimidine compounds, its production and use
WO2000044756A1 (fr) * 1999-01-28 2000-08-03 Takeda Chemical Industries, Ltd. Composes de thiazolopyrimidine, et methodes de preparation et d'utilisation correspondantes
EP1731520A1 (fr) 1999-12-02 2006-12-13 OSI Pharmaceuticals, Inc. Dérivés de pyrrolo[2,3-d]pyrimidine comme antagonistes d'adénosine A1, A2A et A3
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7598252B2 (en) 2000-12-01 2009-10-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A, receptors and uses thereof
EP2050751A1 (fr) 2001-11-30 2009-04-22 OSI Pharmaceuticals, Inc. Composés spécifiques aux récepteurs A1 et A3 de l'adénosine et leur utilisation
WO2003048120A2 (fr) 2001-11-30 2003-06-12 Osi Pharmaceuticals, Inc. Composes specifiques des recepteurs a1 et a3 de l'adenosine et leurs utilisations
US7504407B2 (en) 2001-11-30 2009-03-17 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
US7645754B2 (en) 2001-12-20 2010-01-12 Osi Pharmaceuticals, Inc. Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use
US7501407B2 (en) 2001-12-20 2009-03-10 Osi Pharmaceuticals, Inc. Pyrimidine A2B selective antagonist compounds, their synthesis and use
WO2005063246A1 (fr) * 2003-12-29 2005-07-14 Can-Fite Biopharma Ltd. Methode de traitement de la sclerose en plaques
US7465715B2 (en) 2003-12-29 2008-12-16 Can-Fite Biopharma, Ltd. Method for treatment of multiple sclerosis
US7423144B2 (en) 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
US8609833B2 (en) 2004-05-26 2013-12-17 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
US8183224B2 (en) 2004-05-26 2012-05-22 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
US7863253B2 (en) 2004-09-20 2011-01-04 Inotek Pharmaceuticals Corporation Purine Derivatives and methods of use thereof
US8133880B2 (en) 2004-09-20 2012-03-13 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
US7732424B2 (en) 2005-11-30 2010-06-08 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
WO2008055711A3 (fr) * 2006-11-09 2008-07-31 Ct De Rech Public De La Sante Utilisation d'un antagoniste de l'adénosine
JP2010509258A (ja) * 2006-11-09 2010-03-25 セントレ・ドゥ・レシェルシェ・パブリック・ドゥ・ラ・サン アデノシンアンタゴニストの使用
WO2008055711A2 (fr) * 2006-11-09 2008-05-15 Centre De Recherche Public De La Sante Utilisation d'un antagoniste de l'adénosine
US9370530B2 (en) 2010-01-11 2016-06-21 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
US9289383B2 (en) 2010-03-26 2016-03-22 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans
US9278991B2 (en) 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
US9718853B2 (en) 2012-01-26 2017-08-01 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-YL)-3,4-dihydroxytetrahydrofuran-2-YL)] methyl nitrate and processes of preparation thereof
US9522160B2 (en) 2013-03-15 2016-12-20 Inotek Pharmaceuticals Corporation Ophthalmic formulations

Similar Documents

Publication Publication Date Title
US5780481A (en) Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
WO1997033879A1 (fr) Composes et methodes d'inhibition selective de l'activation du recepteur a3 de l'adenosine chez l'homme
US7820670B2 (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
Barnes The role of anticholinergics in chronic obstructive pulmonary disease
TWI444366B (zh) 作為磷酸二酯酶抑制劑之１－苯基－２－吡啶烷基醇衍生物
US6245789B1 (en) HIV and viral treatment
US11547681B2 (en) N-acylethanolamide derivatives and uses thereof
US20070249644A1 (en) Compounds and methods for the treatment of asthma
Barnes New drugs for asthma
US9370530B2 (en) Combination, kit and method of reducing intraocular pressure
JP2002526408A (ja) 疼痛および不安の処置のためのｍｇｌｕｒ５アンタゴニスト
JP2012131829A (ja) そう痒状態の処置のためのｍｇｌｕｒ５アンタゴニストの使用
TW202003503A (zh) 治療纖維化疾病之方法
CA2813743C (fr) Transporteur selectif de folates couples aux protons et recepteur des folates, et garftase et/ou autres composes inhibiteurs d'enzymes metabolisant les folates et procedes d'utili sation de ceux-ci
CN111253327A (zh) 羧胺三唑类化合物或其盐在制备治疗nlrp3炎症小体活化相关疾病的药物中的应用
ZA200102637B (en) MGluR5 antagonists for the treatment of pain and anxiety.
JP3056879B2 (ja) 自己免疫疾患処置のための医薬組成物
EP3397627B1 (fr) Dérivés d'indolizine, composition et méthodes d'utilisation
GB2320430A (en) Inhibiting activation of the human A3 adenosine receptor
US5137904A (en) Thiohydantoin inhibitors of collagen-induced and ADP-induced platelet aggregation
WO2006050241A1 (fr) Antagonistes ep4 de la prostaglandine
AU768640B2 (en) Drug targeting
AU774981B2 (en) Thiazolopyrimidines useful as TNFalpha inhibitors
WO1991018608A1 (fr) Emploi d'antagonistes de facteur d'activation plaquettaire comme agents antipruritiques
KR20020023675A (ko) 프레가발린을 포함하는 천식 치료용 제약 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97532718

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase